Table 1 Baseline demographic and disease characteristics
All patients with AML-MRC (N = 262) | LDAC-preselected patients with AML-MRC (n = 160) | |||
|---|---|---|---|---|
Azacitidine (n = 129) | CCR (n = 133) | Azacitidine (n = 81) | LDAC (n = 79) | |
Age (years), median (min, max) | 76 (64, 90) | 75 (65, 87) | 76 (64, 90) | 75 (65, 87) |
Age ≥ 75 years, n (%) | 77 (60) | 69 (52) | 55 (68) | 41 (52) |
Male gender, n % | 81 (63) | 78 (59) | 42 (52) | 43 (54) |
Prior history of MDS*, n (%) | 44 (34) | 35 (26) | 32 (40) | 20 (25) |
ECOG PS, n (%) | ||||
0–1 | 94 (73) | 104 (78) | 56 (69) | 64 (81) |
2 | 35 (27) | 29 (22) | 25 (31) | 15 (19) |
Cytogenetic risk, n (%) | ||||
Intermediate | 63 (49) | 61 (46) | 47 (58) | 33 (42) |
Poor | 66 (51) | 72 (54) | 34 (42) | 46 (58) |
No. of dysplastic lineages, n (%) | ||||
0–1 | 57 (44) | 52 (39) | 36 (44) | 35 (44) |
2–3 | 72 (56) | 81 (61) | 45 (56) | 44 (56) |
% BM blasts, median (min, max) | 65.0 (27, 99) | 70.0 (26, 100) | 66.0 (27, 99) | 69.0 (31, 100) |
Haematology, median (min, max) | ||||
ANC (109/L) | 0.4 (0.0, 11.6) | 0.3 (0.0, 8.7) | 0.4 (0.0, 11.6) | 0.3 (0.0, 8.7) |
Platelets (109/L) | 56 (3, 585) | 55 (6, 244) | 58 (7, 585) | 55 (6, 244) |
WBC (109/L) | 3.2 (0.6, 26.5) | 2.4 (0.4, 22.6) | 2.6 (0.6, 26.5) | 2.3 (0.4, 13.5) |
Hgb (g/dL) | 9.5 (5.0, 13.4) | 9.3 (5.0, 14.4) | 9.4 (5.0, 11.8) | 9.4 (5.6, 14.4) |